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Abstract
Activating point mutations in the K-Ras oncogene are among the most common genetic alterations 
in pancreatic cancer, occurring early in the progression of the disease. However, the function of 
mutant K-Ras activity in tumor angiogenesis remains poorly understood. Using human pancreatic 
duct epithelial (HPDE) and K-Ras4BG12V–transformed HPDE (HPDE-KRas) cells, we show that 
activated K-Ras significantly enhanced the production of angiogenic factors including CXC 
chemokines and vascular endothelial growth factor (VEGF). Western blot analysis revealed that 
K-Ras activation promoted the phosphorylation of Raf/mitogen-activated protein kinase 
kinase-1/2 (MEK1/2) and expression of c-Jun. MEK1/2 inhibitors, U0126 and PD98059, 
significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH2-
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terminal kinase inhibitor SP600125 abrogated only CXC chemokine production. To further 
elucidate the biological functions of oncogenic K-Ras in promoting angiogenesis, we did in vitro 
invasion and tube formation assays using human umbilical vein endothelial cells (HUVEC). 
HUVEC cocultured with HPDE-KRas showed significantly enhanced invasiveness and tube 
formation as compared with either control (without coculture) or coculture with HPDE. Moreover, 
SB225002 (a CXCR2 inhibitor) and 2C3 (an anti-VEGF monoclonal antibody) either alone or in a 
cooperative manner significantly reduced the degree of both Ras-dependent HUVEC invasiveness 
and tube formation. Similar results were obtained using another pair of immortalized human 
pancreatic duct–derived cells, E6/E7/st and its oncogenic K-Ras variant, E6/E7/Ras/st. Taken 
together, our results suggest that angiogenesis is initiated by paracrine epithelial secretion of CXC 
chemokines and VEGF downstream of activated oncogenic K-Ras, and that this vascular 
maturation is in part dependent on MEK1/2 and c-Jun signaling.
Introduction
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, 
with approximately 32,000 newly diagnosed cases and an equal number of deaths occurring 
annually (1). The poor prognosis of pancreatic cancer is attributable to its tendency for late 
presentation, aggressive local invasion, early metastases, and poor response to chemotherapy 
(2). As a result, a better understanding of the fundamental nature of this cancer is needed to 
improve the clinical outcome. The majority of pancreatic cancers arise from cells of ductal 
origin, and one of the earliest genetic events in the progression of these normal ductal 
epithelia to premalignant pancreatic intraepithelial neoplasia is mutation of the K-Ras 
oncogene (3, 4). Moreover, because mutational activation of Ras proteins is seen with such 
high frequency (90%) in pancreatic ductal adenocarcinoma (5), it is reasonable to consider 
that clarifying the role of K-Ras in pancreatic cancer carcinogenesis and targeting this 
signaling pathway is fundamental to improving clinical response.
The growth of malignant solid tumors is dependent on the development of new blood 
vessels that provide oxygen and nutrients to the tumor cells (6), and it is well established 
that tumor growth beyond the size of 1 to 2 mm is angiogenesis-dependent (7–9). 
Furthermore, given that pancreatic cancer usually presents clinically with distal metastasis 
and this malignant spread is often via the vasculature, neoangiogenesis is a critical element 
of both primary tumor growth and subsequent spread of the disease. Because oncogenic K-
Ras mutation is one of the earliest genetic events in the progression of these normal ductal 
epithelia to premalignant pancreatic intraepithelial neoplasia, it is reasonable to hypothesize 
that angiogenesis is affected by increased K-Ras signaling. However, little is known about 
the role of oncogenic K-Ras mutation in angiogenesis in the early stages of pancreatic 
cancer.
Angiogenesis is a complex process involving extracellular matrix remodeling, endothelial 
cell migration and proliferation, and capillary tube formation (10). Angiogenesis is 
determined by a balance between angiogenic and angioinhibitory factors (11, 12). Many 
reports have shown the expression of various proangiogenic factors in pancreatic cancer 
angiogenesis. Among them, vascular endothelial growth factor (VEGF) and CXC 
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chemokines, including CXCL1/growth-related oncogene-α, CXCL5/epithelial-neutrophil 
activating protein-78, and CXCL8/interleukin-8, were described as key players of an-
giogenesis in pancreatic cancer (13–15). Ikeda et al. showed the relation between K-Ras 
gene and VEGF expression by quantitative reverse transcriptase-PCR (RT-PCR) analysis 
and immunohistochemical analysis (16). However, the biological role of oncogenic K-Ras in 
VEGF production from pancreatic duct epithelial cells has not been clearly elucidated. Also, 
there are few reports detailing the correlation between K-Ras mutation and CXC chemokine 
expression in pancreatic cancer.
In the present study, we show that oncogenic K-Ras promotes the production of angiogenic 
CXC chemokines and VEGF from immortalized human pancreatic duct–derived epithelial 
cells, and that this enhancement is in part dependent on mitogen-activated protein kinase 
kinase-1/2 (MEK1/2) and c-Jun signaling. Our in vitro biological assays also showed that 
up-regulated VEGF and CXC chemokine secretion enhance the invasion and tube formation 
potencies of human umbilical vein endothelial cells (HUVEC). To our knowledge, this is the 
first report describing the biological effects of the oncogenic K-Ras on angiogenesis in 
human pancreatic duct epithelial (HPDE) cells.
Results
Expression of Oncogenic K-Ras Activates Multiple Downstream Effector Pathways in 
HPDE-KRas Cells
We initially confirmed up-regulated Ras activation in HPDE-KRas cells by Ras-GTP-Raf 
affinity precipitation assay (Fig. 1A) as first shown by Tsao and colleagues (17). We next 
examined the effect of oncogenic K-Ras on the proliferation and invasion of HPDE cells. 
Despite the activation of several growth-promoting (VEGF, pMEK1/2, c-Jun; Fig. 1B) and 
anti-apoptotic and survival (cIAP1, Bcl-2, Bcl-xL, cyclin D1; Fig. 1C) pathways, mutant K-
Ras did not affect either proliferative (in agreement with previous observations; ref. 17) or 
invasive potency in HPDE cells (Supplementary Fig. S1). Based on these data, we focused 
our attention on the paracrine effects resulting from oncogenic K-Ras expression in 
epithelial cells.
Because Raf kinases are commonly activated by GTP-loaded K-Ras, we sought to determine 
if the Raf/MEK/extracellular signal-regulated kinase (ERK) pathway is persistently 
activated in HPDE-KRas cells. Although the levels of activated MEK1/2 were increased in 
HPDE-KRas compared with control HPDE cells, expression of both activated and total 
ERK1/2 was decreased. This contrasts with observations made in the majority of cell models 
of Ras transformation, in which ectopic expression of mutant Ras causes persistent ERK 
activation (18, 19). However, these data are concordant with those reported for pancreatic 
carcinoma cell lines, in which elevated MEK phosphorylation was independent of ERK 
activation (20), and previous reports have shown that mitogen-activated protein kinase 
phosphatase-2 (MKP-2) expression increased with the activation of MEK (21). We also 
found that MKP-2 expression in HPDE-KRas was significantly higher than that of HPDE, 
possibly contributing to decreased steady-state phosphorylated ERK1/2 (p-ERK1/2). 
Whereas previous reports showed that up-regulated ERK phosphorylation downstream of 
oncogenic K-Ras in these cells, those data resulted from confluent cultures under starvation 
Matsuo et al. Page 3






















conditions (17). We did not starve subconfluent populations of cells prior to harvesting for 
Western blotting, and the differences in these culture conditions may also have contributed 
to the decreases in p-ERK that we consistently observed. We next determined the activation 
of several other known Ras effector pathways in this model system. Compared with HPDE 
cells, the mutant Ras-expressing counterparts showed elevated levels of both total c-Jun and 
activated c-Jun (Fig. 1B). We did an electrophoretic mobility shift assay to assess the effect 
of oncogenic K-Ras on nuclear factor κB (NF-κB) activity. Mutant K-Ras did not elevate 
the NF-κB activity in HPDE cells (data not shown). Finally, using Western blot analysis, we 
showed elevated expression of both the angiogenic enzyme cyclooxygenase-2 (COX-2) and 
the angiogenic cytokine VEGF as a consequence of oncogenic K-Ras mutation (Fig. 1B).
Expression of CXCR2, VEGFR1, and VEGFR2 in HPDE and HPDE-KRas Cell Lines
As our focus of this study was K-Ras–induced CXC chemokine and VEGF secretion from 
pancreatic ductal epithelium cells as paracrine stimuli on vascular endothelial cells, we 
investigated the expression of the target receptors CXCR2, VEGFR1, or VEGFR2 in HPDE 
and HPDE-KRas cells to reveal any potential autocrine effects of these cytokines. We used 
HUVEC as a positive control. No mRNA expression of these receptors could be seen in 
parental HPDE or HPDE-KRas cell lines (Fig. 1D). We further showed a lack of autocrine 
signaling for these cytokines in both HPDE cell lines by performing an in vitro proliferation 
assay (MTS assay). Agonists CXCL8 and VEGF or inhibitors SB225002 and 2C3 did not 
affect either HPDE or HPDE-KRas proliferation (Supplementary Fig. S2).
Oncogenic K-Ras Induces Both CXC Chemokines and VEGF Production from HPDE Cells 
through MEK and/or c-Jun Pathways
To evaluate whether oncogenic K-Ras expression promotes the production of angiogenic 
factors from HPDE cells, we next measured the concentrations of CXC chemokines or 
VEGF in HPDE or HPDE-KRas supernatants by ELISA. K-Ras activation significantly 
enhanced both CXC chemokine and VEGF production from HPDE cells (Fig. 2A and B).
Because K-Ras activated the downstream signaling molecule pMEK1/2, we examined the 
effect of MEK1/2 inhibitors U0126 and PD98059 on Ras-induced CXC chemokines and 
VEGF production. Both inhibitors significantly reduced both CXC chemokines and VEGF 
production driven by oncogenic K-Ras (Fig. 2C and D).
As oncogenic K-Ras activation promoted the expression and phosphorylation of c-Jun, we 
wanted to see if this pathway had a role in the release of CXC chemokines and VEGF. 
Treatment of cells with the c-Jun inhibitor SP600125 significantly reduced CXC chemokine 
secretion from HPDE-KRas (Fig. 2C). In contrast, SP600125 did not affect oncogenic K-
Ras–induced VEGF production (Fig. 2D).
Oncogenic K-Ras Enhances HUVEC Invasion and Endotube Formation by Promoting CXC 
Chemokine and VEGF Secretion from HPDE Epithelial Cells
Because active K-Ras enhanced the production and secretion of proangiogenic factors from 
HPDE cell lines, we hypothesized that these agents might result in K-Ras–related 
angiogenesis. To examine the interaction between HPDE cell lines and HUVEC, we used a 
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double-chamber coculture system to look at HUVEC motility. Coculture with HPDE-KRas 
cells significantly enhanced HUVEC invasion potency compared with either medium alone 
(control) or coculture with HPDE cells (Fig. 3A and B). Additionally, to elucidate the 
mechanism of K-Ras–induced invasion of vascular endothelial cells, we treated HUVEC 
with the CXCR2 antagonist SB225002 and/or 2C3, an antibody against VEGFR2. Although 
SB225002 and 2C3 had no effect on the limited activity of HPDE cells to stimulate HUVEC 
invasion, both drugs significantly inhibited the enhanced HUVEC invasion driven by 
oncogenic K-Ras. Moreover, the combination of SB225002 and 2C3 completely blocked the 
enhanced HUVEC invasion by HPDE-KRas (Fig. 3C and D), indicating that both CXC and 
VEGF epithelial production downstream of activated K-Ras have paracrine effects on 
vascular endothelial cell motility.
Following these studies on HUVEC invasion, we next examined the paracrine effect of 
oncogenic K-Ras on HUVEC tube formation. To show an interaction between HPDE cell 
lines and HUVEC, we again used the two-chamber coculture system. Coculture of HUVEC 
with HPDE-KRas cells significantly enhanced HUVEC endotube formation as compared 
with growth medium alone (control) or coculture with HPDE cells (Fig. 4A and B). To 
further investigate the role of mutant K-Ras–induced CXC chemokines and VEGF in 
HUVEC tube formation potency, we treated HUVEC with SB225002 and 2C3. In contrast 
to observations with invasion assays, HPDE-augmented endotube formation was partially 
inhibited by the CXCR2 inhibitor SB225002 or a neutralizing antibody against the receptor 
(Supplementary Fig. S4). Both SB225002 and 2C3 inhibited HUVEC tube formation 
enhanced by oncogenic K-Ras; the combination of the two inhibitors completely blocked 
both enhanced HUVEC tube formation and native tube growth potential (Fig. 4C and D). 
These inhibitors indicate that the normal ability of HUVEC to organize into structures 
(control in Fig. 4B1) is at least in part dependent on endogenous VEGF and CXCR 
signaling.
Oncogenic K-Ras Enhances the Production of Both CXC Chemokines and VEGF from 
E6/E7/st Cell Lines
To solidify our findings on the effect of oncogenic K-Ras on angiogenesis in more detail, we 
used another pair of immortalized human pancreatic duct–derived cells: E6/E7/st and its 
oncogenic K-Ras variant, E6/E7/Ras/st. Initially, we did an ELISA of CXC chemokines and 
VEGF, and showed that production of both cytokines from E6/E7/st cell lines was 
significantly enhanced by mutant K-Ras expression (Fig. 5A and B). Although K-Ras–
driven CXC chemokine production was significantly inhibited by treatment with MEK1/2 
inhibitors, U0126 and PD98059, the c-Jun NH2-terminal kinase inhibitor SP600125 did not 
affect the secretion of CXC chemokines (Fig. 5C). All three inhibitors, U0126, PD98059, 
and SP600125, diminished VEGF release from E6/E7/Ras/st cells (Fig. 5D).
Mutant K-Ras Stimulates Both HUVEC Invasion and Endotube Formation in E6/E7/Ras/st 
Cells via Multiple Signaling Pathways
Western blot analysis confirmed that activated K-Ras enhanced the expression of the 
proangiogenic factors COX-2 and VEGF in E6/E7/Ras/st cells compared with parental 
controls (Fig. 6A). E6/E7/Ras/st cells showed significantly enhanced HUVEC invasion 
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compared with E6/E7/st cells, and the enhancement was inhibited by the combination of 
SB225002 and 2C3 (Fig. 6B; Supplementary Fig. S3A). E6/E7/Ras/st cells significantly 
augmented the length and complexity of HUVEC endotube structures compared with 
controls (without coculture) and E6/E7/st cells. This enhancement was significantly 
inhibited by SB225002 and/or 2C3 (Fig. 6C; Supplementary Fig. S3B).
Discussion
It has been well established that the initiation and progression of pancreatic cancer is driven 
in part by a series of genetic mutations, including mutations of K-Ras, CDKN2A, TP53, 
BRCA2, and SMAD4/DPC4, which occur early in the development of ductal cell dysplasia 
(3, 22). Less clear is which of the many mutations are critical for pancreatic cancer 
development, and what the roles of the different proteins may be. Because activating 
mutations of K-Ras are in evidence in early pancreatic intraepithelial neoplasias, and K-Ras 
mutations are found in >90% of patients with pancreatic cancer (23), and because 
downstream signaling due to K-Ras can contribute to all of the characteristics of malignant 
progression (24), it is tempting to believe that mutant K-Ras is critical for many aspects of 
pancreatic cancer. In addition to the direct changes in epithelial cells as a result of genetic 
alterations, a growing area of interest includes the signaling cross-talk that happens among 
tumor epithelial cells, the surrounding stroma, and vascular tissue. Our goal for this 
experimental study was to investigate such paracrine effects of hyperactive K-Ras protein in 
pancreatic duct–derived epithelial cells on vascular endothelial cells. Our data clearly 
indicated that oncogenic K-Ras induced the production of angiogenic factors from HPDE 
cells, and that as a consequence, invasion and tube formation of HUVEC were significantly 
enhanced.
We initially showed that in spite of Ras-dependent increases in both growth-promoting and 
antiapoptotic/survival proteins, there was no significant difference in proliferation between 
HPDE and HPDE-KRas. However, Tsao and colleagues have previously shown that the 
tumorigenic potential of HPDE-KRas cells in severe combined immunodeficiency mice was 
significantly increased compared with HPDE cell lines (17). This result suggests that tumor 
growth was enhanced by the paracrine effects of oncogenic K-Ras as opposed to simple 
augmented growth rate. Because one of the most important interactions between the tumor 
and its microenvironment is angiogenesis, and because neoangiogenesis is a rate-limiting 
step in tumor expansion, in the present study, we focused our attention on vascular network 
initiation. The production of the known angiogenic factors CXC chemokines and VEGF 
were significantly enhanced (5-fold and 2-fold at 48 hours, respectively) by the expression 
of mutant K-Ras in the epithelial cells. These enhanced cytokines did not affect HPDE-
KRas cells in an autocrine manner, as evidenced by the absence of change in proliferation, 
but significantly enhanced both invasion and tube formation of HUVEC in coculture assays. 
These results seem to explain the previous report that oncogenic K-Ras had little effect on 
HPDE contact–independent growth but enhanced tumorigenic potential in vivo (17), and 
suggests that paracrine cross-talk between tumor cells and the microenvironment is 
important in the malignancy of pancreatic cancer.
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The best-characterized effector pathway in oncogene K-Ras function is the Raf/MEK/ERK 
cascade (25). In our HPDE and HPDE-KRas system, mutant K-Ras expression enhanced 
MEK activation but did not up-regulate ERK activation, similar to results reported for 
pancreatic carcinoma cell lines, in which elevated MEK was independent of ERK activation 
(20). Instead, similar to previous results in other pancreatic cell systems (21, 26), our data 
showed that oncogenic K-Ras increased the expression of the phosphatase MKP-2 in these 
HPDE cell systems. Although activation of the Ras/MEK/ERK signaling axis has been 
shown to increase proliferation, it is possible that hyperactivation of these pathways may be 
detrimental to cell growth. Others have similarly shown a disconnect between activated 
MEK and activated ERK, suggesting that p-ERK may not be the most relevant marker of 
pathway stimulation in all situations (27, 28). Whether augmented MEK-dependent MKP-2 
expression plays a pro-oncogenic role or is simply a compensatory mechanism to reduce 
overactive ERK1/2 is unclear and warrants further study in the future. It is tempting to 
believe, however, that because this increase in MKP-2 is seen in a wide range of both 
pancreatic cancer cell lines and Ras-transformed pancreatic cells, this phosphatase plays an 
important role in the progression of this tumor type. We next examined whether enhanced 
MEK activation by oncogenic K-Ras promoted the production of angiogenic factors from 
HPDE cell systems. Blocking of MEK signaling by U0126 or PD98059 significantly 
inhibited the production of both CXC chemokines and VEGF from HPDE-KRas, indicating 
that proangiogenic factor secretion is modulated at least in part by Ras-dependent MEK1/2 
activation. It is possible that substrates of MKP-2 that remain phosphorylated in the face of 
decreased MKP-2 activity due to MEK inhibition could play a role both in the changes seen 
in VEGF and CXC chemokine release and in angiogenesis phenotype. This area remains an 
intriguing opportunity for our ongoing research.
Previous reports showed that K-Ras oncogene expression up-regulates the activity of NF-κB 
(29). NF-κB is an important transcription factor involved in the production of VEGF and in-
terleukin-8 in pancreatic cancer (30, 31), and has been associated with pancreatic 
carcinogenesis (32–35). Indeed, previously published data showed that NF-κB is 
constitutively activated in most (>70%) human pancreatic cancer cell lines and primary 
tumor specimens (35). We did electrophoretic mobility shift assays to assess NF-κB activity 
in both HPDE and HPDE-KRas cells, using TNF-α stimulated KBM-5 cells as a positive 
control, but found no significant difference in NF-κB activity between the cell lines (data 
not shown). These results indicate that NF-κB is not activated by oncogenic K-Ras in this 
model system, and NF-κB may not participate in the production of angiogenic factors in the 
early stages of pancreatic cancer. It does not, however, preclude a role for NF-κB–driven 
VEGF at other points of pancreatic cancer development, particularly the vascular expansion 
necessary for distal metastasis. Because the phosphoinositide 3-kinase/AKT pathway is 
another major downstream effector cascade stimulated by K-Ras signaling (36, 37), we 
examined the effect of phosphoinositide 3-kinase/AKT pathway on the Ras-induced 
production of angiogenic factors in the HPDE cell system. Using the phosphoinositide 3-
kinase inhibitor LY294002, we saw no significant effect on factor secretion (data not 
shown), suggesting that activation of phosphoinositide 3-kinase is not critical for CXC and 
VEGF release.
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Previous reports have indicated that the K-Ras downstream c-Jun pathway plays an 
important role in cell survival regulation in pancreatic cancer (38). Indeed, our Western blot 
analysis showed increased c-Jun activation by hyperactivated K-Ras in HPDE cell systems. 
Our present study showed that the c-Jun NH2-terminal kinase inhibitor SP600125 
significantly inhibited CXC chemokine production, but not VEGF production, in the HPDE 
cell system. In contrast, VEGF production from the E6/E7/st cell system was significantly 
inhibited by SP600125, but SP600125 did not inhibit the CXC chemokine production from 
the E6/E7/st cell model. It may be that more complex mechanisms might be involved in the 
mutant K-Ras/c-Jun pathways and one of the future directions of our study will be to clarify 
this signaling.
In summary, we found that oncogenic K-Ras enhanced the production and secretion of CXC 
chemokines and VEGF from both HPDE and E6/E7/st immortalized pancreatic epithelial 
cell systems that were in part dependent on MEK1/2 and c-Jun signaling. Consequently, 
these enhanced proangiogenic factors promoted the invasion and tube formation of HUVEC 
in coculture systems in vitro. The results of our experiments clearly showed that oncogenic 
K-Ras mutation in ductal epithelial cells contributes in a paracrine manner to the initiation 
and maturation of vascular endotubes, a critical hurdle in the early development of 
pancreatic cancer. These data further illustrate the importance of the K-Ras signaling 
cascade in pancreatic cancer malignancy, the necessity to understand the multifaceted roles 
of Ras in order to advance therapeutic options for pancreatic cancer (39), and the increasing 
field of research focused on cross-talk among epithelial, stromal, and vascular cell 
populations in tumor development.
Materials and Methods
Cell Culture
HUVECs were obtained from Lonza Walkersville, Inc. HU-VEC were maintained in 
endothelial growth media-2 (EGM-2; Lonza) with EGM-2 singlequots (Lonza), which 
contained 2% FCS. The HPDE cells and K-Ras4BG12V–transfected HPDE (HPDE-KRas) 
cells were generous gifts from Dr. Ming-Sound Tsao (17, 40). These cells were cultured in 
keratinocyte serum-free medium supplied with 5 ng/mL of epidermal growth factor and 50 
μg/mL of bovine pituitary extract (Invitrogen). A second pair of immortalized normal human 
pancreatic duct epithelial cell lines with or without mutant oncogenic K-Ras (G12D; 
E6/E7/Ras/st and E6/E7/st, respectively) were also used. Briefly, these cells were pancreatic 
duct–derived cells from the healthy pancreas of a 52-year-old accident victim. The cells 
were immortalized by ectopic expression of the catalytic subunit of human telomerase and 
HPV16 E6 and E7, and were subsequently transformed by expression of SV40 small T 
antigen and mutant K-RasG12D (26, 41, 42). These were maintained in M3/5 growth medium 
[four parts high-glucose DMEM to one part M3F (INCELL Corp.) supplemented with 5% 
FCS]. All cells were incubated at 37°C in a humidified atmosphere of 5% CO2 in air.
Reagents and Antibodies
The following antibodies against VEGF, COX-2, and MKP-2 were obtained from Santa 
Cruz Biotechnology. The antibodies against p-ERK1/2, ERK1/2, p-Raf/MEK, p-c-Jun, and 
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c-Jun were obtained from Cell Signaling Technology, Inc. Antibodies against β-actin was 
obtained from Sigma-Aldrich, Co. 2C3, anti-VEGF monoclonal antibody, which is shown to 
block the interaction of VEGF with VEGFR2, was kindly given by Dr. Rolf A. Brekken 
(University of Texas Southwestern Medical Center, Dallas, TX). MEK inhibitors U0126 and 
PD98059, c-Jun NH2-terminal kinase inhibitor SP600125, and the antagonist of G protein–
coupled chemokine receptor CXCR2, SB225002 were obtained from Calbiochem.
Ras Activation Assay
Initially, we reconfirmed the expression of activated Ras in HPDE and HPDE-KRas cells by 
Ras Activation Assay kit (Upstate Biotechnology, Inc.) following the instructions of the 
manufacturer. Briefly, cells were washed twice with ice-cold PBS and lysed in 1× Mg2+ 
lysis/washing buffer containing protease inhibitors (Roche Molecular Biochemicals) for 15 
min at 4°C. Cell lysates were centrifuged at 1,000 × g for 20 min and the protein 
concentrations of the supernatants were then determined by BCA protein assay kit (Pierce). 
Equal amounts of samples (400 μg) were immediately affinity-precipitated using 20 μg of 
Ras assay reagent (agarose-conjugated Raf-1 RBD) for 45 min at 4°C. The precipitates were 
washed thrice with 1× Mg2+ lysis/washing buffer and eluted by boiling in 2× SDS-PAGE 
reducing sample buffer. The proteins were separated on a 12% SDS-polyacrylamide gel and 
then immunoblotted with a pan-Ras antibody supplied in the Upstate kit (RAS10). The same 
antibody was used to determine total K-Ras amounts. Positive and negative assay controls 
for Ras activation were cell lysate ectopically loaded with GTPγS and GDP, respectively.
Western Blot
Total cell lysates from confluent cultures were prepared using ice-cold lysis buffer [150 
mmol/L NaCl, 50 mmol/L Tris-HCl (pH 8.0), 1% Nonidet P40, 0.1% SDS, 0.5% 
deoxycholate-Na, 1 mmol/L sodium orthovanadate, 1 mmol/L sodium fluoride, plus 
protease inhibitors]. Fifty micrograms of protein from cell lysates were separated on 10% or 
12% SDS-PAGE gels and transferred to Immobilon transfer membranes. The membrane 
was incubated in blocking buffer (5% nonfat dry milk in TBS containing 0.1% Tween 20) 
for 1 h at room temperature. The membrane was incubated with primary antibody overnight 
at 4°C. The membrane was washed with TBS containing 0.1% Tween 20, and incubated for 
1 h with secondary anti-mouse or anti-rabbit peroxidase-linked antibodies in blocking 
solution at room temperature. After washing, protein-antibody complexes were visualized 
with an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech). 
The membrane was washed and stripped using Restore Western blot stripping buffer 
(Pierce) and β-actin was detected by the same method.
ELISA
HPDE, HPDE-KRas, E6/E7/st, and E6/E7/Ras/st cells were seeded at a density of 2 × 105 
cells/mL into a 24-well plate and cultured overnight. Medium was then exchanged and cells 
were cultured for a further 24, 48, or 72 h. The culture media were then collected and 
microfuged at 1,500 rpm for 5 min to remove insoluble matter, and the supernatants frozen 
at −80°C until use in the ELISA. The concentrations of CXCL1, CXCL5, CXCL8, and 
VEGF were measured using an ELISA kit (R&D Systems) according to the instructions of 
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the manufacturer. The concentrations of individual CXC chemokines were added because 
they are all agonists of CXCR2. To examine the roles of MEK and c-Jun signaling in 
enhanced production of both CXC chemokines and VEGF by oncogenic K-Ras, all cell lines 
were treated with MEK inhibitors U0126 (5 μmol/L) or PD98059 (10 μmol/L), or c-Jun 
NH2-terminal kinase inhibitor SP600125 (20 μmol/L). After 48 h of incubation, the 
supernatants were collected and the concentrations of CXC chemokines or VEGF were 
measured as described above.
RT-PCR Analysis
Total RNA was prepared from all cell lines using an RNeasy Mini Kit by Qiagen. RT-PCR 
was done according to the instructions of the manufacturer using a One-step RT-PCR kit by 
Qiagen. For RT-PCR, we used the following pairs of forward and reverse primer sets: 5′-
aacatggagagtgacagctttg-3′ and 5′-ttagagagtagtggaagtgtg-3′ (CXCR2; PCR product size is 
1,071 bp), 5′-ctatcactgcaaagccacca-3′ and 5′-aagcccctcttccaagtgat-3′ (VEGFR1; PCR 
product size is 329 bp), and 5′-gcatggtcttctgtgaagca-3′ and 5′-ttcctccaactgccaatacc-3′ 
(VEGFR2; PCR product size is 806 bp). PCR was done for 35 cycles with denaturation at 
94°C for 60 s, annealing at 54°C for 60 s, and extension at 72°C for 60 s. Amplified DNA 
fragments were resolved by electrophoresis on 1.2% agarose gels containing ethidium 
bromide. β-Actin was used as a positive control.
HUVEC Proliferation Assay
To confirm the effects of oncogenic K-Ras on the proliferation of HPDE cells, we did a 
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS assay; Promega) 
according to the instructions of the manufacturer. Briefly, HPDE or HPDE-KRas cells were 
seeded at a density of 2 × 103 cells/100 μL in 96-well plates. After 12, 36, 60, and 84 h of 
incubation, 20 μL of CellTiter 96 AQueous One Solution Reagent was added to each well and 
the trays were incubated for 3 h at 37°C, after which absorbance was measured using a 
micro-plate reader with a test wavelength of 490 nm.
HUVEC Invasion Assay
The invasive potency of HUVEC was determined by invasion assays using the BD Bio-Coat 
Matrigel invasion assay system (BD Biosciences) which was done according to the 
instructions of the manufacturer. We used a double-chamber method to determine the effect 
of coculturing with HPDE, HPDE-KRas, E6/E7/st, or E6/E7/Ras/st cells on HUVEC 
invasiveness. HUVEC cells (5 × 104) were seeded into the upper transwell chambers with 8 
μm pores, which were then placed into 24-well plates in which HPDE, HPDE-KRas, 
E6/E7/st, or E6/E7/Ras/st cells (1 × 105 cells) or medium only (control) were preseeded. 
After 16 h of incubation, the upper surface of the transwell chambers was wiped with a 
cotton swab and the invading cells were fixed and stained with Diff-Quik stain (Dade-
Behring). Invading cells were counted in five random microscopic fields (×200). Similarly, 
to examine the effect of oncogenic K-Ras–induced CXC chemokines or VEGF on HUVEC 
invasiveness, HUVEC were pretreated with CXCR2 antagonist SB225002 (100 nmol/L) 
and/or anti-VEGFR2 antibody 2C3 (100 nmol/L) for 1 h. Then the effect on HUVEC 
invasiveness was determined as above.
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Tube Formation Assay for Angiogenesis on Matrigel
HUVEC tube formation potency was measured by angiogenesis assay on Matrigel (BD 
Biosciences). For reconstitution of a basement membrane matrix, Matrigel was diluted 2-
fold with cold DMEM (without FCS) and added to the 24-well tissue culture plate (250 μL/
well) at 4°C. The 24-well plate was incubated for 2 h at 37°C to allow the Matrigel to 
solidify. HUVECs were trypsinized, counted, resuspended in basal medium, and added on 
top of the reconstructed basement membrane (5 × 104 cells/well). To evaluate the effect of 
the oncogenic K-Ras on HUVEC tube formation, we used a double-chamber method. 
HPDE, HPDE-KRas, E6/E7/st, or E6/E7/Ras/st cells (1 × 104 cells) were seeded into 
transwell chambers consisting of polycarbonate membranes with 0.4 μm pores (BD 
Biosciences) and allowed to adhere overnight. The chambers were then placed into the 
HUVEC tube formation assay system. Cells were incubated for 16 h to allow the formation 
of capillary-like structures. These endotubes were quantified by counting nine random 
microscopic fields (×40) per sample, with each condition being assessed in triplicate. 
Similarly, to examine the effect of cell line–induced CXC chemokine or VEGF secretion on 
HUVEC tube formation, HUVEC were pre-treated with CXCR2 antagonist SB225002 (100 
nmol/L) and/or anti-VEGFR2 antibody 2C3 (100 nmol/L) for 1 h. HUVEC tube formation 
potency was determined in the same way.
Statistical Analysis
Multiple group comparisons were done by using one-way ANOVA with a post hoc test, 
Student-Newman-Keuls test, or the Dunnett test for subsequent individual group 
comparisons. Differences between the two groups were evaluated using Student’s t test. P < 
0.05 was considered statistically significant. Mean values and SD were calculated for 
experiments done in triplicate (or more).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Oncogenic K-ras stimulates downstream signaling of multiple effectors. A. Confirmation of 
K-Ras oncogene expression in HPDE-KRas: total and GTP-bound Ras proteins were 
detected by Western blotting using a pan-Ras antibody. Positive controls (P.C.) and negative 
controls (N.C.) for Ras activation as described in Materials and Methods. B and C. 
Activation of regulatory, signaling, and survival proteins in HPDE-KRas cells. B, whole-cell 
lysate Western blot analyses for p-ERK1/2, total ERK1/2, pMEK1/2, MKP-2, p-c-Jun, total 
c-Jun, COX-2, VEGF, and β-actin (n = 3 independent experiments); C, ICAM-1, cyclin D1, 
survivin, cIAP-1, Bcl-2, and Bcl-xL (n = 2 independent experiments) as described in 
Materials and Methods. D. Detection of CXCR2, VEGFR1, and VEGFR2 mRNA in HPDE 
and HPDE-KRas cells by RT-PCR as described in Materials and Methods. HUVEC 
transcript was used as a positive control.
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Oncogenic K-Ras expression in HPDE-Ras cells triggers the secretion of CXC and VEGF 
chemokines via mitogen-activated protein kinase pathways. A and B. Cultured (24 or 48 h) 
media from HPDE and HPDE-KRas cells were collected. The summed (Σ) concentrations of 
CXCL1, CXCL5, and CXCL8 chemokines (A), or VEGF (B) were measured by ELISA and 
are expressed as mean ± SD (*, P < 0.01; **, P < 0.05 as described in Materials and 
Methods). C and D. Reduction of CXC chemokine and VEGF production from HPDE and 
HPDE-KRas cells by blocking MEK or c-Jun signaling. C. HPDE or HPDE-KRas cells 
were treated with U0, PD, or SP. Media (48 h) CXC chemokines concentration was 
measured as described in Materials and Methods (*, P < 0.01 compared with control). D. 
Similarly, the effect on VEGF production from HPDE or HPDE-KRas cells by U0, PD, or 
SP was determined as described in Materials and Methods. Columns, mean values 
representative of two or more independent experiments done in triplicate; bars, SD (*, P < 
0.01 compared with control).
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HPDE-KRas enhances HUVEC invasion via both CXCR2 and VEGFR2 signaling. A and B. 
The alteration of HUVEC invasion through Matrigel by coculture with HPDE or HPDE-
KRas cell lines: HUVEC cells were seeded into Matrigel transwell chambers cocultured 
with HPDE or HPDE-KRas cells or medium only (control). Invading cells were fixed at 16 
h, stained and counted as described in Materials and Methods. Columns, mean fold 
(compared with control); bars, SD (*, P < 0.01; **, P < 0.05). C and D. Blockade of 
CXCR2 and/or VEGFR2 signaling inhibits HUVEC invasion. HUVEC were pretreated with 
SB225002 and/or 2C3 for 1 h before HU-VEC invasiveness was determined, as described in 
Materials and Methods. Columns, mean fold (compared with control); bars, SD (*, P < 0.01 
compared with no treatment; **, P < 0.01 compared with 2C3 + SB). Columns, mean values 
representative of two or more independent experiments done in triplicate; bars, SD.
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HPDE-KRas enhances angiogenesis via both CXCR2 and VEGFR2 signaling. A and B. 
HUVEC were cocultured with HPDE or HPDE-KRas cells as described in Materials and 
Methods. Columns, mean fold of control; bars, SD (*, P < 0.01). C and D. Blockade of 
CXCR2 and/or VEGFR2 signaling inhibits the HUVEC tube formation enhanced by HPDE-
KRas. HUVEC were pretreated with SB225002 and/or 2C3 for 1 h. HUVEC tube formation 
was determined as described in Materials and Methods. Columns, mean; bars, SD (*, P < 
0.01 compared with no treatment; **, P < 0.01 compared with 2C3 + SB). Columns, mean 
values representative of three or more independent experiments done in triplicate; bars, SD.
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Oncogenic K-Ras expression in E6/E7/Ras/st cells stimulates the secretion of CXC and 
VEGF chemokines via mitogen-activated protein kinase pathways. A and B. CXC 
chemokine production from E6/E7/st or E6/E7/Ras/st cells. Culture media from growing 
E6/E7/st or E6/E7/Ras/st cells were collected (24, 48, and 72 h) and summed concentrations 
of CXCL1, CXCL5, and CXCL8 chemokines (A) or VEGF (B) were measured by ELISA as 
described in Materials and Methods. Columns, mean; bars, SD (*, P < 0.01). C and D. CXC 
chemokines and VEGF production is reduced by blocking MEK and c-Jun signaling. Media 
from E6/E7/st or E6/E7/Ras/st cells treated with U0, PD, or SP were collected at 48 h as 
described in Materials and Methods. CXC chemokines (C) or VEGF (D) concentrations are 
expressed as mean fold ± SD (*, P < 0.01 compared with control). Columns, mean values 
representative of two or more independent experiments done in triplicate; bars, SD.
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Oncogenic K-ras expression in E6/E7/st/Ras cells stimulates proangiogenic factor 
expression and paracrine invasion and tubule formation of HUVEC. A. Western blot of 
COX-2 and VEGF expression as described in Materials and Methods, representative of n = 3 
experiments. B. E6/E7/Ras/st enhances the invasion of HUVEC via both CXCR2 and 
VEGFR2 signaling. Naïve HUVEC cells or HUVEC pretreated with SB and/or 2C3 for 1 h 
were cocultured with E6/E7/st or E6/E7/Ras/st cells or medium only (control) for 16 h as 
described in Materials and Methods (*, P < 0.01; and **, P < 0.05 compared with 
E6/E7/Ras/st). C. E6/E7/Ras/st enhanced the tube formation by HUVEC via both CXCR2 
and VEGFR2. HUVEC and E6/E7/st or E6/E7/Ras/st were cocultured for 16 h as described 
in Materials and Methods, and endotubes were counted from nine random fields per sample. 
As above, HUVEC were pretreated with SB and/or 2C3 for 1 h. Columns, mean fold; bars, 
SD (*, P < 0.01 compared with E6/E7/Ras/st). Columns, mean values representative of two 
or more independent experiments done in triplicate; bars, SD.
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